This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
symptomatic 50% to 69% carotid stenosis and the quality of life of stroke survivors (after major and minor stroke).
Study designs and other criteria for inclusion in the review
The estimates for the risks of strokes and death were based on the North American Symptomatic Carotid Endarterectomy Trial (NASCET), a randomised controlled trial analysing the carotid endarterectomy versus best medical treatment. The design of studies providing evidence for the other outcomes was not reported.
Sources searched to identify primary studies
Not reported.
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
Seven references providing the outcome estimates were cited.
Methods of combining primary studies
The parameters for which estimates were identified were combined into a Markov decision analytic model.
Investigation of differences between primary studies
Results of the review
The results of the review were as follows:
The 30-day probabilities of stroke and death were 6.6% for CEA (minor stroke, 4.6%; major stroke, 0.8%; and death, 1.2%) and 2.4% for the medically treated patients (minor stroke, 1%; major stroke, 1%; and death, 0.4%).
The decremental risk of an ipsilateral stroke after the first 30 days for the medically treated patients was 9.3% for the first year (major 2.6%, minor 6.7%); 4% for the second year (major 1.1%, minor 2.9%); and 3% for subsequent years (major 0.4%, minor 1.6%)
The decremental risk of an ipsilateral stroke after the first 30 days surgical patients was 3% for the first year (major 0.6%, minor 2.4%); and 2% for subsequent years (major 0.9%, minor 2.1%).
Fatality of major strokes was estimated at 18% and the survivors had an excess mortality rate of 7.7% per year.
The mortality rate of the patients with 50% to 69% carotid stenosis was estimated to be 6.3% higher per annum than the age-specific mortality of the US population.
The quality of life of survivors of major stroke was estimated at 0.4 annually.
Methods used to derive estimates of effectiveness
The authors made some assumptions to support the data used in the decision model.
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Estimates of effectiveness and key assumptions
A minor stroke was estimated to result in an overall disutility of 0.25 years. The benefit of the surgical treatment was assumed to persist for 5 years after endarterectomy. After 5 years, medical and surgical stroke risks were equivalent at 3% per year.
Measure of benefits used in the economic analysis
The benefit was measured in Quality-Adjusted Life-Years (QALYs). The valuation technique was not reported. A 3% discount rate was used for future QALYs.
Direct costs
A 3% discount rate was used since the time horizon of the study was considerably longer than two years. The analysis of costs included costs of CEA, health care costs of stroke (inpatient, outpatient, home health care and nursing home care cost) and cost of aspirin therapy. The cost/resource boundary adopted in the analysis was not explicitly stated. The cost of carotid endarterectomy (including anaesthesia) of $6,420 was based on the cost at New York Presbyterian HospitalCornell Campus. The direct costs of stroke ($9,300 for hospitalisation for minor stroke, $798 annual outpatient cost after minor stroke, $51,150 for the first year after major stroke and $26,880 for subsequent years) were estimated from the literature. It was assumed that 30% of survivors of major stroke would undergo inpatient rehabilitation followed by outpatient and home health care, while the remainder would reside in nursing homes. Patients who did not develop stroke were assumed to be on aspirin therapy at an annual cost of $63. The quantities of resources were not reported separately from the unit costs. The price year was not reported.
Statistical analysis of costs
The costs were not treated stochastically.
Indirect Costs
No indirect costs were included in the analysis.
Currency

US dollars ($).
Sensitivity analysis
A wide range of sensitivity analyses was performed to explore the sensitivity of the cost-effectiveness results. These included one-way sensitivity analyses of the 30 day risk of stroke and death in medical and surgical patients from 3% to 11%, reduction of the first year risk of stroke in the range 1% to 8%, reduction in the 3rd to 5th year risk of stroke in the range 0% to 2%, unit costs of CEA, annual cost of major and minor strokes, patients' age, and QALY score for major stroke in the range 0.2 to 1.
